Resolving the source of branch length variation in the Y chromosome phylogeny.

Background: Genetic variation in the non-recombining part of the human Y chromosome has provided important insight into the paternal history of human populations. However, a significant and yet unexplained branch length variation of Y chromosome lineages has been observed, notably amongst those that are highly diverged from the human reference Y chromosome. Understanding the origin of this variation, which has previously been attributed to changes in generation time, mutation rate, or efficacy of selection, is important for accurately reconstructing human evolutionary and demographic history.

Earliest modern human genomes constrain timing of Neanderthal admixture.

Modern humans arrived in Europe more than 45,000 years ago, overlapping at least 5,000 years with Neanderthals. Limited genomic data from these early modern humans have shown that at least two genetically distinct groups inhabited Europe, represented by Zlatý kůň, Czechia and Bacho Kiro, Bulgaria. Here we deepen our understanding of early modern humans by analyzing one high-coverage genome and five low-coverage genomes from ~45,000 year-old remains from Ilsenhöhle in Ranis, Germany, and a further high-coverage genome from Zlatý kůň.

Metastability demystified - the foundational past, the pragmatic present and the promising future.

Healthy brain function depends on balancing stable integration between brain areas for effective coordinated functioning, with coexisting segregation that allows subsystems to express their functional specialization. Metastability, a concept from the dynamical systems literature, has been proposed as a key signature that characterizes this balance. Building on this principle, the neuroscience literature has leveraged the phenomenon of metastability to investigate various aspects of brain function in health and disease.

Safety and Feasibility of Peanut, Tree Nut, and Sesame Oral Immunotherapy in Infants and Toddlers in a Real-World Setting.

Background: Oral immunotherapy (OIT) for food allergy has been largely studied in older children within the context of clinical trials, and its availability has historically been limited for younger patients with food allergy. Data have shown that the most impact may actually be seen with the use of OIT in younger infants and toddlers.

Objective: To evaluate the safety and feasibility of OIT in subjects 24 months and younger in a real-world setting using commercially available food products.